George D. Yancopoulos

2019

In 2019, George D. Yancopoulos earned a total compensation of $20.7M as President and Chief Scientific Officer at Regeneron Pharmaceuticals, a 19% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,598,510
Option Awards$11,699,586
Salary$1,170,500
Stock Awards$4,983,226
Other$212,313
Total$20,664,135

Yancopoulos received $11.7M in option awards, accounting for 57% of the total pay in 2019.

Yancopoulos also received $2.6M in non-equity incentive plan, $1.2M in salary, $5M in stock awards and $212.3K in other compensation.

Rankings

In 2019, George D. Yancopoulos' compensation ranked 142nd out of 13,971 executives tracked by ExecPay. In other words, Yancopoulos earned more than 99.0% of executives.

ClassificationRankingPercentile
All
142
out of 13,971
99th
Division
Manufacturing
53
out of 5,692
99th
Major group
Chemicals And Allied Products
13
out of 2,189
99th
Industry group
Drugs
11
out of 1,875
99th
Industry
Pharmaceutical Preparations
10
out of 1,387
99th
Source: SEC filing on April 24, 2020.

Yancopoulos' colleagues

We found four more compensation records of executives who worked with George D. Yancopoulos at Regeneron Pharmaceuticals in 2019.

2019

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer

2019

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2019

Robert Landry

Regeneron Pharmaceuticals

Chief Financial Officer

2019

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

News

In-depth

You may also like